SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 8-K
CURRENT REPORT Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 16, 2000
SYMBOLLON CORPORATION
(Exact name of Registrant as specified in its charter)
Delaware 0-22872 36-3463683
---------------------------- ----------- ------------------------------------
(State or other jurisdiction (Commission (I.R.S. Employer Identification No.)
of incorporation) File Number)
37 Loring Drive, Framingham, Massachusetts 01702
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:
(508) 620-7676
-------------------------
Not Applicable
-------------------------
(Former name or former address, if changed since last report.)
<PAGE>
Item 5. Other Events
------------
On August 16, 2000 Symbollon announced favorable preliminary
results of a Phase II clinical trial for its patented drug, IoGen(TM). A
copy of the press release is attached hereto as Exhibit 99.1 and incorporated
by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
------------------------------------------------------------------
(c) Exhibits.
--------
99.1 August 16, 2000 Press Release of the Company.
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
August 18, 2000 SYMBOLLON CORPORATION
By: /s/ Paul C. Desjourdy
------------------------------
Paul C. Desjourdy
President, Chief Operating Officer
and Chief Financial Officer
<PAGE>
INDEX TO EXHIBITS
Exhibit No. Description Page No.
----------- ----------- --------
99.1 August 16, 2000 of the Company.
